Medistim ASA has transferred 8000 shares to CEO Kari Krogstad's 100% owned
company K2 Consulting. This is according to the agreement entered between
Medistim ASA and the CEO under the same terms as described in the press release
from the 22end of January 2024. The shares have a lock up period of 3 years and
this qualifies for a 25% discount. Average share price in the 14 days
subscription period was NOK 193 per share. The shares were therefore purchased
at 144,56 per share.
To finance the purchase, Medistim has given the CEO a loan and when the lock in
period has ended, she is given a bonus equal to the loan amount. K2 Consulting
AS has in total 23.500 shares after the purchase.
After these transactions Kari E. Krogstad controls in total 70.583 Medistim
shares. Medistim ASA has 23.117 own shares after the transactions.